104 89

Cited 0 times in

Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.

DC FieldValueLanguage
dc.contributor.author정현철-
dc.date.accessioned2017-02-27T08:07:12Z-
dc.date.available2017-02-27T08:07:12Z-
dc.date.issued2016-
dc.identifier.issn1598-2998-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/147092-
dc.description.abstractPURPOSE: This study analyzed the role of plasma biomarkers for TSU-68 in a previous phase II trial comparing TSU-68 plus docetaxel and docetaxel alone in patients with metastatic breast cancer. MATERIALS AND METHODS: A total of 77 patients were eligible for this study (38 in the TSU-68 plus docetaxel arm and 39 in the docetaxel alone arm). Blood samples were collected prior to the start of each cycle, and vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-AA, -AB, -BB, fibroblast growth factor, M30, C-reactive protein (CRP), and interleukin 6 (IL-6) levels were measured using enzyme linked immunosorbent assay. The primary endpoint was progression-free survival (PFS). RESULTS: In patients with baseline PDGF-AA ≥ median, median PFS was significantly worse in the TSU-68 plus docetaxel group than in the docetaxel alone group (5.4 months vs. 13.7 months, p=0.049), while a trend toward a PFS benefit was observed in those with baseline PDGF-AA < median (9.7 months vs. 4.0 months, p=0.18; p for interaction=0.03). In the TSU-68 plus docetaxel group, PFS showed significant association with fold changes in CRP (p=0.001), IL-6 (p < .001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treatment cycle. CONCLUSION: Baseline PDGF-AA levels and dynamics of VEGF, PDGF-BB, CRP, and IL-6 levels were predictive for the efficacy of TSU-68.-
dc.description.statementOfResponsibilityopen-
dc.format.extent499~507-
dc.languageEnglish, Korean-
dc.publisherOfficial journal of Korean Cancer Association-
dc.relation.isPartOfCancer Research and Treatment-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAngiogenesis Inhibitors/administration & dosage-
dc.subject.MESHAngiogenesis Inhibitors/pharmacology*-
dc.subject.MESHAngiogenesis Inhibitors/therapeutic use*-
dc.subject.MESHAntineoplastic Agents/administration & dosage-
dc.subject.MESHAntineoplastic Agents/pharmacology-
dc.subject.MESHAntineoplastic Agents/therapeutic use-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols-
dc.subject.MESHBiomarkers, Tumor/blood*-
dc.subject.MESHBreast Neoplasms/blood*-
dc.subject.MESHBreast Neoplasms/drug therapy*-
dc.subject.MESHBreast Neoplasms/pathology-
dc.subject.MESHC-Reactive Protein/analysis-
dc.subject.MESHEnzyme-Linked Immunosorbent Assay-
dc.subject.MESHFemale-
dc.subject.MESHFibroblast Growth Factors/blood-
dc.subject.MESHHumans-
dc.subject.MESHIndoles/administration & dosage-
dc.subject.MESHIndoles/pharmacology*-
dc.subject.MESHIndoles/therapeutic use*-
dc.subject.MESHInterleukin-6/blood-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Metastasis/drug therapy*-
dc.subject.MESHPropionates/administration & dosage-
dc.subject.MESHPropionates/pharmacology*-
dc.subject.MESHPropionates/therapeutic use*-
dc.subject.MESHTaxoids/administration & dosage-
dc.subject.MESHTaxoids/pharmacology-
dc.subject.MESHTaxoids/therapeutic use-
dc.subject.MESHVascular Endothelial Growth Factor A/blood-
dc.titleCirculating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.-
dc.typeArticle-
dc.publisher.locationKorea-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorChanghoon Yoo-
dc.contributor.googleauthorSung-Bae Kim-
dc.contributor.googleauthorJungsil Ro-
dc.contributor.googleauthorSeock-Ah Im-
dc.contributor.googleauthorYoung-Hyuck Im-
dc.contributor.googleauthorJee Hyun Kim-
dc.contributor.googleauthorJin-Hee Ahn-
dc.contributor.googleauthorKyung Hae Jung-
dc.contributor.googleauthorHong Suk Song-
dc.contributor.googleauthorSeok Yun Kang-
dc.contributor.googleauthorHee Sook Park-
dc.contributor.googleauthorHyun-Cheol Chung-
dc.identifier.doi10.4143/crt.2015.089-
dc.contributor.localIdA03773-
dc.relation.journalcodeJ00453-
dc.relation.journalsince2001~-
dc.identifier.pmid26194374-
dc.relation.journalbefore~2001 Journal of the Korean Cancer Research Association (대한암학회지)-
dc.subject.keywordAngiogenesis-
dc.subject.keywordBiological markers-
dc.subject.keywordBreast neoplasms-
dc.subject.keywordPharmacology-
dc.subject.keywordTSU-68-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.citation.volume48-
dc.citation.number2-
dc.citation.startPage499-
dc.citation.endPage507-
dc.identifier.bibliographicCitationCancer Research and Treatment, Vol.48(2) : 499-507, 2016-
dc.date.modified2017-02-24-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.